

### Remarks

As requested by the Examiner, enclosed is a sequence listing showing the four sequences referred to in the specification. No new matter was added because SEQ ID NOS: 1 and 2 were publicly available on Genebank and EMBL and referred to in the specification on page 21, line 2, and SEQ ID NOS: 3 and 4 were shown in the specification on page 21, lines 6-7. Therefore, applicants submit that they are now in compliance with the requirements of 37 CFR §§ 1.821-1.825.

Claim 33 was amended to insert the phrase "analogs and" after "epoxyeicosatrienoic acid" and before "dihydroxyeicosatrienoic acid analogs" to make the claim language consistent with claim 28, and the "and" in line 3 was replaced with "or" as requested by the Examiner.

Claim 34 was amended to remove the duplicated phrase "wherein the".

Claim 40 was amended to remove the "s" at the end of products as requested by the Examiner. In view of these amendments, Applicants request that the objection to the claims be withdrawn.


Material to be deleted from the claims is shown with a strike-through. Please note that the brackets shown in claims 35 and 40 are part of the chemical name, and do NOT represent deleted materials.

If any matters remain before a Notice of Allowance is issued, the Examiner is invited to telephone the undersigned at the number below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446